Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4535 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-08-31

Study Completion Date

2019-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bexsero™ is a four component serogroup B meningococcal vaccine (4CMenB) licensed in Europe, Canada, and Australia in 2014. Prelicensure studies and post marketing surveillance data showed that 4CMenB has a high reactogenicity especially when coadministered with other infant routine vaccines \[1-2\]. While this suggests that coadministration causes an interaction resulting in a greater risk of adverse events following Immunization (AEFI) only the AEFI after the 4CMenB dose and not those occurring after routine vaccine immunizations were reported, underestimating the total risk associated with immunization at separate visits. For financial and practical reasons, coadministration of infant vaccines is preferred to separate visits. Separate visits may however be preferred if the sum of the AEFI risk at each visit is significantly smaller than the risk with coadministration and/or if the AEFI has a lesser severity. The purpose of this study is to recalculate the risk of occurrence and severity of AEFI with the coadministration of Bexsero™ and routine vaccines compared to separate injections to assess the interaction occurring with co-administration. Investigators will also estimate the risk of recurrence of AEFI at subsequent immunizations with the 4CMenB and assess if this risk varies with separate or coadministration with routine vaccines. To achieve these purposes, investigators will perform a secondary analysis of the data of three randomized controlled trials (clinicaltrials.gov identifiers: NCT00657709, NCT00847145 and NCT00721396) that evaluated 5025 children aged 2 to 14 months of whom 4535 were randomized to receive 3 to 4 doses of 4CMenB concomitantly or alternatively with routine vaccinations (DTaP-Inactivated polio virus -HepatitisB/Haemophilus influenzae type b \[Infanrix Hexa™\], Pneumococcal conjugate vaccine, 7 valent \[Prevenar™\] or Measles-Mumps-Rubella-Varicella vaccine \[Priorix-Tetra™\]) \[1,2\].

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

NCT03587207

Meningitis, Meningococcal

COMPLETED PHASE2

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

NCT03632720

Healthy Volunteers (Meningococcal Infection)

COMPLETED PHASE3

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers

NCT01340898

Meningococcal Infection

COMPLETED PHASE3

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

NCT00657709

Serogroup B Meningococcal Meningitis

COMPLETED PHASE3

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

NCT03673462

Healthy Volunteers (Meningococcal Infection)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meningococcal Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Coadministration B_RV246

Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar).

4CMenb

Intervention Type BIOLOGICAL

diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention Type BIOLOGICAL

conjugated pneumococcal vaccine

Intervention Type BIOLOGICAL

Coadministration B_RV234

Subjects in this group received 4CMenB vaccine at 2, 3 and 4 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar)..

4CMenb

Intervention Type BIOLOGICAL

diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention Type BIOLOGICAL

conjugated pneumococcal vaccine

Intervention Type BIOLOGICAL

Coadministration B_MMRV12

Subjects in this group previously received three doses of 4CMenB and routine vaccine at 2, 4 and 6 months of age,respectively. They also received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine.

4CMenb

Intervention Type BIOLOGICAL

diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention Type BIOLOGICAL

conjugated pneumococcal vaccine

Intervention Type BIOLOGICAL

MMRV

Intervention Type BIOLOGICAL

Separate administration B246_RV357

Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age; routine infant vaccinations (Infanrix Hexa+Prevenar) were administered at 3, 5 and 7 months of age.

4CMenb

Intervention Type BIOLOGICAL

diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention Type BIOLOGICAL

conjugated pneumococcal vaccine

Intervention Type BIOLOGICAL

Separate administration B12_MMRV13

Subjects in this group previously received three doses of 4CMenB and routine vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age. They also received a booster (fourth) dose of 4CMenB at 12 months of age and one dose of MMRV vaccine at 13 months of age.

4CMenb

Intervention Type BIOLOGICAL

diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention Type BIOLOGICAL

conjugated pneumococcal vaccine

Intervention Type BIOLOGICAL

MMRV

Intervention Type BIOLOGICAL

Routine vaccines only at 2, 3 and 4 months of age (RV234)

Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 3 and 4 months of age.

diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention Type BIOLOGICAL

conjugated pneumococcal vaccine

Intervention Type BIOLOGICAL

Routine vaccines only at 2, 4 and 6 months of age.(RV246)

Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age.

diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention Type BIOLOGICAL

conjugated pneumococcal vaccine

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

4CMenb

Intervention Type BIOLOGICAL

diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB

Intervention Type BIOLOGICAL

conjugated pneumococcal vaccine

Intervention Type BIOLOGICAL

MMRV

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bexsero Infanrix Hexa Prevenar Priorix Tetra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy 2-month old infants (55-89 days, inclusive), who were born after full term pregnancy with an estimated gestational age ≥ 37 weeks
* Parent/legal guardian has given written informed consent after the nature of the study has been explained.

Exclusion Criteria

* History of any meningococcal B or C vaccine administration; prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens);
* Previous ascertained or suspected disease caused by N. meningitidis; History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;
* Significant acute or chronic infection within the previous 7 days or axillary temperature major or equal to38 degrees within the previous day;
* Antibiotics within 6 days prior to enrollment;
* Any serious chronic or progressive disease;
* Known or suspected impairment or alteration of the immune system;
* Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation.

Minimum Eligible Age

2 Months

Maximum Eligible Age

14 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes